Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV0113 in Refractory Childhood Solid Tumours
NCT02533895Phase 1Completed
- Sponsor
- Activartis Biotech GmbH
- Start
- Feb 2000
- Primary completion
- Aug 2015
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of audencel in Solid tumors and sarcoma (2 arms), sponsored by Activartis Biotech GmbH. Primary endpoints: Overall Survival at 15 years, Overall Survival Comparison vs Historic Control at 15 years and 3 more. Started Feb 2000; status: completed.
02
Drugs
audencel
03
Conditions
Solid tumorssarcoma
Beyond the preview
Go deeper on NCT02533895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02533895.